IMPLEMENTATION ROLLING PLAN Regulation (EU) 2017/745 and Regulation (EU) 2017/746

This rolling plan contains a list of identified essential implementing acts and other relevant initiatives that the Commission has adopted or intends to adopt in the future. This plan is divided into two sections: implementing acts, and other actions/initiatives. This document is subject to quarterly review in order to provide national authorities and stakeholders with the most updated information.

This document shall be read in conjunction with the "MDR/IVDR roadmap" adopted by the Competent Authorities for Medical Devices (CAMD) in cooperation with the Commission (available at https://www.camd-europe.eu/regulatory/medical-devices-regulation-vitro-diagnostics-regulation-mdr-ivdr-roadmap). A list of ongoing MDCG guidance documents is available at https://ec.europa.eu/docsroom/documents/37921.

NOTE: Regulation (EU) 2020/561 of the European Parliament and of the Council deferred by one year the date of application of Regulation (EU) 2017/745, until 26 May 2021.

Latest update: December 2020

| No. Subject | Legal basis | Description | Expected timelines (expected date of final adoption/date of accomplishment) | State-of-play/Next step |
|--------------------------------------|------------------------|--|---|--|
| | | IMPLEMENTING ACTS | | |
| | Article 42(13) MDR | Commission Implementing Regulation (EU) 2017/2185 | | |
| Notified bodies scope of designation | Article 38(13) IVDR | Definition of the list of codes and corresponding types of devices for the purpose of specifying the scope of the designation of notified bodies. This action is an essential precondition for the launch of the designation procedure for Notified Bodies | 24 November 2017 | Published on 24 November 2017 COMPLETED |
| Reprocessing of single-use devices | e Article 17(5) MDR | Commission Implementing Regulation (EU) 2020/1207 Common specifications laying down requirements related to reprocessing of single-use devices concerning risk management, including the analysis of the construction and material, related properties of the device (reverse engineering) and procedures to detect changes in the design of the original device as well as of its planned application after reprocessing; the validation of procedures for the entire process, including cleaning steps; the product release and performance testing; the quality management system; the reporting of incidents involving devices that have been reprocessed; and the traceability of reprocessed devices. | Q3 2020 | Published on 20 August 2020 COMPLETED |

| No | Subject | Legal basis | Description | Expected timelines (expected date of final adoption/date of accomplishment) | State-of-play/Next step |
|----|---|--|--|---|--|
| 3 | Common specifications for products without a medical purpose | Articles 1(2) and 9(1) MDR | Commission implementing act Common specifications (CS) addressing for any of the groups of products listed in Annex XVI of the MDR, at least, application of risk management as set out in Annex I and, where necessary, clinical evaluation regarding safety. Application of MDR to Annex XVI products depends on the adoption of CS. | Q2 2021 | In progress. |
| 4 | Setting up of expert panels | recital 94 Article 106(1) MDR | Commission Implementing Decision (EU) 2019/1396 Making provision for expert panels to be designated. Based on this implementing act, the selection of experts will be carried out. Expert panels are tasked inter alia with the delivery of opinions on the clinical evaluation of certain high-risk devices in the context of the premarket scrutiny. Tasks of expert panels are described in Article 106(10). | Q3 2019 | Published on 10 September 2019. COMPLETED |
| 5 | Setting up of expert laboratories | Article 106(7) MDR | Commission implementing act Designation of expert laboratories. Tasks of expert laboratories are described in Article 106(7). It shall be noted that the designation of expert laboratories is not mandatory. | - | Not in planning. |
| 6 | Setting up of new structures under IVDR: - EU reference laboratories | recital 94 Articles 48(6), 100(1) and (3) IVDR, Article 113(d) IVDR | Implementing Act (no comitology involved) Designation of EU reference laboratories, active in the IVD field. Tasks are described in Article 100. Designation may take place no earlier than 25 November 2020, according to IVDR Article 113(d). | Q3-4 2021 | In preparation |
| 7 | Rules to facilitate fulfilment of tasks by EU reference laboratories and to ensure their compliance with criteria | Article 100(8)(a) | Implementing Act Rules to facilitate application of IVDR Article 100 (2) listing the tasks of the EURLs; rules to ensure compliance with criteria for an EURL listed in IVDR Article 100 (4). Date of application of the act may not be earlier than 25 November 2020 according to IVDR Article 113(d). | Q1 2021 | In progress |
| 9 | Fees for EURL services | Article 100(8)(b) IVDR | Implementing Act Definition of rules for fees for the advice/testing activities performed by EURL. Date of application of the act may not be earlier than 25 November 2020 according to IVDR Article 113(d). | Q1 2021 | In progress |
| 10 | Unique Device Identification (UDI) System: designation of issuing entities | Article 27(2) MDR Article 24(2) IVDR | Commission Implementing Decision (EU) 2019/939 Designation of one or more entities to operate a system for assignment of UDIs ('issuing entity'). | 6 June 2019 | Published on 6 June 2019. COMPLETED |

| No. | Subject | Legal basis | Description | Expected timelines (expected date of final adoption/date of accomplishment) | State-of-play/Next step |
|-------------|---|---|---|---|--|
| 11 E | UDAMED | Article 33(8) MDR Article 30(1) IVDR | Commission implementing act Definition of detailed arrangements necessary for the setting up and maintenance of Eudamed. This IA is mainly related to support, change management and maintenance rules | Q1 2021 | In progress |
| 12 | Common specifications for VD Class D | Article 9 and 48(6) IVDR | Commission implementing act Common Specifications for certain IVDs in class D. Important to facilitate conformity assessment by manufacturers, notified bodies, expert panels and EU reference laboratories | Q2 2021 | In progress |
| | | | ACTIONS/INITIATIVES (OTHER THAN IMPLEMENTING REGULATI | ONS/ACTS) | |
| 1 | lotified Bodies lesignation | | Designation of Notified Bodies under the MDR and IVDR. Designation of Notified Bodies under the Regulations is a pre-condition for carrying out conformity assessments under those Regulations. List of notified bodies under MDR/IVDR available at: https://ec.europa.eu/growth/tools-databases/nando/index.cfm?fuseaction=directive.main | Notified bodies are designated on a roling basis. | See New Approach Notified and Designated Organisations (NANDO). |
| 5 E | UDAMED go-live | Article 34 MDR | Eudamed may go-live from the moment a notice is published in the Official Journal of the European Union after a positive independent audit was performed that satisfies the MDCG | Notice to be published in 2022. | Deployment of fully functional EUDAMED intended to take place in 2022. In agreement with the MDCG, the Commission has pledged to make available the six modules on a roling basis as soon as each module becomes operational. |

| No | o. Subject | Legal basis | Description | Expected timelines (expected date of final adoption/date of accomplishment) | State-of-play/Next step |
|----|--|-------------------|---|---|---|
| 3 | EUDAMED: drawing up of functional specifications | Article 34(1) MDR | Functional specifications for Eudamed, to be drawn up by the Commission, in cooperation with the MDCG. | Q1 2019 (high-level functional specifications) | High-level functional specifications publically issued on the Commission website in March 2019. |
| 4 | EUDAMED: Audit of functional specifications | Article 34(2) MDR | Independent audit report based on which the Commission shall inform the MDCG that Eudamed has achieved full functionality and meets the drawn up functional specifications. | Should be finalised in 2022. | Pending. |

| No. | Subject | Legal basis | Description | Expected timelines (expected date of final adoption/date of accomplishment) | State-of-play/Next step |
|-----|--|-------------------------------|---|---|--|
| 6 | EUDAMED: Setting of helpdesk | MDR Art 33(8) | Detailed arrangements necessary for the setting up and maintenance of Eudamed means at least the setting of an helpdesk/application support for Eudamed (good IT practice and obligation under the implementing act). | Before Eudamed go-live | Available for Actor registration - UDI Helpdesk Q1 2021 |
| 7 | Communication campaign | | In order to avoid bottle necks and to ensure access to medical devices, a communication campaign targeting all stakeholders impacted by the Regulations is foreseen at least for 3 years. Targeted factsheets are produced for each target and the webpages of DG GROW on medical devices will be updated to provide more accurate and updated information. | Updated information to be provided during the transitional period of the Regulations. Examples of deliverables are information factsheets, targeted presentations, dedicated website. | The website dedicated to the Medical Devices Regulations is live. It has been transferred to SANTE webpages and it is continuously being updated. Social media campaign and targeted press release currently ongoing. Notifications are sent to subscribers of the Newsletter when new documents are published on the website. |
| 8 | Expert advisory structure: Setting of MDCG | Article 103 MDR | Establishing the Medical Devices Coordination Group (MDCG). The Group is composed of designated experts from Member States and chaired by the Commission. The Group provides advice and guidance on all matters related to the implementation of the Regulations. | 26 November 2017 (Legal deadline) | Established by the legal deadline COMPLETED |
| 9 | Expert advisory structure: Setting of MDCG subgroups | Article 103 MDR | Setting of MDCG sub-groups, providing MDCG with the necessary expertise in relation to specific fields. | Establishment of MDCG Subgroup started in March 2019 | Multiple MDCG Subgroups for different areas of the Regulations operational since March 2019. Latest Subgroup (on EUDAMED) established in April 2020. COMPLETED |
| 10 | Mandate to SCHEER on phthalates | Annex I Section 10.4.3 MDR | Mandate to the scientific Committee (SCHEER) to prepare guidelines on phthalates. Available at: https://ec.europa.eu/health/sites/health/files/scientific_committees/scheer/docs/scheer_o_015.pdf | 18 June 2019 | Adopted on 18 June 2019. COMPLETED |
| 11 | EU medical device nomenclature | Article 26 MDR and 23 IVDR | Designation of the future EU medical device nomenclature to be used in the UDI database | March 2019 | Decision published on the Commission website in March 2019. $ {\it COMPLETED} \\$ |
| 12 | Standardisation Request | • | MDR/IVDR Standardisation Request by the Commission to the relevant European estandardisation organisations (CEN and CENELEC) for development of harmonised European standards in the field of medical devices in support of the requirements of the new Regulations. The existing standards harmonised under the current Directives need to be revised to align them to the new legislative framework, and new standards need to be developed | Q1 2021 | After the rejection by CEN/CENELEC of the act adopted by the Commission in June 2020, a new draft of the Commission Implementing Decision for the MDR/IVDR Standardisation Request is under development, to be submitted to the opinion of the Committee on Standards, then to be adopted by the Commission and addressed to CEN/CENELEC for their acceptance. |